Adiponectin–leptin ratio for the early detection of lean non-alcoholic fatty liver disease independent of insulin resistance

References

• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Scorletti E, Mosca A, et al. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020;111s:154170.
   PubMed Web of Science ®Google Scholar
• Tilg H, Effenberger M. From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol. 2020;17(7):387–388.
   PubMed Web of Science ®Google Scholar
• Luukkonen PK, Qadri S, Ahlholm N, et al. Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease. J Hepatol. 2022;76(3):526–535.
   PubMed Web of Science ®Google Scholar
• Muzurović E, Polyzos S, Mikhailidis D, et al. Non-alcoholic fatty liver disease in children. Curr Vasc Pharmacol. 2022.Nov 18.doi: 10.2174/1570161121666221118155136. Online ahead of print.
   Web of Science ®Google Scholar
• Muzurović E, Peng CC, Belanger MJ, et al. Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors. Hypertension. 2022;79(7):1319–1326.
   PubMed Web of Science ®Google Scholar
• Méndez-Sánchez N, Bugianesi E, Gish RG, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7(5):388–390.
   PubMed Web of Science ®Google Scholar
• Loomis AK, Kabadi S, Preiss D, et al. Body mass index and risk of nonalcoholic fatty liver disease: two electronic health record prospective studies. J Clin Endocrinol Metab. 2016;101(3):945–952.
   PubMed Web of Science ®Google Scholar
• Feldman A, Eder SK, Felder TK, et al. Clinical and metabolic characterization of lean Caucasian subjects with non-alcoholic fatty liver. Am J Gastroenterol. 2017;112(1):102–110.
   PubMed Web of Science ®Google Scholar
• Younes R, Govaere O, Petta S, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Gut. 2022;71(2):382–90.
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209.
   PubMed Web of Science ®Google Scholar
• Ballestri S, Lonardo A, Romagnoli D, et al. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int. 2012;32(8):1242–1252.
   PubMed Web of Science ®Google Scholar
• Calori G, Lattuada G, Ragogna F, et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology. 2011;54(1):145–152.
   PubMed Web of Science ®Google Scholar
• Eguchi A, Wree A, Feldstein AE. Biomarkers of liver cell death. J Hepatol. 2014;60(5):1063–1074.
   PubMed Web of Science ®Google Scholar
• Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270(45):26746–26749.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425–432.
   PubMed Web of Science ®Google Scholar
• Myers MG, Cowley MA, Münzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol. 2008;70:537–556.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116(7):1784–1792.
   PubMed Web of Science ®Google Scholar
• Lu JY, Huang KC, Chang LC, et al. Adiponectin: a biomarker of obesity-induced insulin resistance in adipose tissue and beyond. J Biomed Sci. 2008;15(5):565–576.
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Kountouras J, Mantzoros CS. Leptin in nonalcoholic fatty liver disease: a narrative review. Metabolism. 2015;64(1):60–78.
   PubMed Web of Science ®Google Scholar
• Straub LG, Scherer PE. Metabolic messengers: adiponectin. Nat Metab. 2019;1(3):334–339.
   PubMedGoogle Scholar
• Frühbeck G, Catalán V, Rodríguez A, et al. Adiponectin-leptin ratio is a functional biomarker of adipose tissue inflammation. Nutrients. 2019;11(2):454. doi: 10.3390/nu11020454
   Web of Science ®Google Scholar
• Frühbeck G, Catalán V, Rodríguez A, et al. Adiponectin-leptin ratio: a promising index to estimate adipose tissue dysfunction. Relation with obesity-associated cardiometabolic risk. Adipocyte. 2018;7(1):57–62.
   PubMed Web of Science ®Google Scholar
• Hwang JH, Hsu CJ, Liu TC, et al. Adiponectin beyond cardiometabolic disorders. J Formos Med Assoc. 2011;110(12):796–797.
   PubMed Web of Science ®Google Scholar
• Zhao S, Kusminski CM, Scherer PE. Adiponectin, leptin and cardiovascular disorders. Circ Res. 2021;128(1):136–149.
   PubMed Web of Science ®Google Scholar
• Mikami K, Endo T, Sawada N, et al. Adiponectin/leptin ratio correlates with hepatic steatosis but not arterial stiffness in nonalcoholic fatty liver disease in Japanese population. Cytokine. 2020;126:154927.
   PubMed Web of Science ®Google Scholar
• Angın Y, Arslan N, Kuralay F. Leptin-to-adiponectin ratio in obese adolescents with nonalcoholic fatty liver disease. Turk J Pediatr. 2014;56(3):259–266.
   PubMed Web of Science ®Google Scholar
• Boutari C, Mantzoros CS. Adiponectin and leptin in the diagnosis and therapy of NAFLD. Metabolism. 2020;103:154028.
   PubMed Web of Science ®Google Scholar
• Kim YS, Lee SH, Park SG, et al. Low levels of total and high-molecular-weight adiponectin may predict non-alcoholic fatty liver in Korean adults. Metabolism. 2020;103:154026.
   PubMed Web of Science ®Google Scholar
• Sahin-Efe A, Upadhyay J, Ko BJ, et al. Irisin and leptin concentrations in relation to obesity, and developing type 2 diabetes: a cross sectional and a prospective case-control study nested in the normative aging study. Metabolism Clin Exp. 2018;79:24–32.
   PubMed Web of Science ®Google Scholar
• Cernea S, Roiban AL, Both E, et al. Serum leptin and leptin resistance correlations with NAFLD in patients with type 2 diabetes. Diabetes Metabolism Res Rev. 2018;34(8):e3050.
   PubMed Web of Science ®Google Scholar
• Lu CW, Lee YC, Chiang CH, et al. Independent dose-response associations between Fetuin-A and lean nonalcoholic fatty liver disease. Nutrients. 2021;Aug 24;13(9):2928. doi:10.3390/nu13092928.
   Web of Science ®Google Scholar
• Lee YC, Lee YH, Chuang PN, et al. The utility of visceral fat level measured by bioelectrical impedance analysis in predicting metabolic syndrome. Obes Res Clin Pract. 2020;14(6):519–523.
   PubMed Web of Science ®Google Scholar
• Kao TW, Peng TC, Chen WL, et al. Higher serum leptin levels are associated with a reduced risk of sarcopenia but a higher risk of dynapenia among older adults. J Inflamm Res. 2021;14:5817–5825.
   PubMed Web of Science ®Google Scholar
• (a) Lemoine M, Ratziu V, Kim M, et al. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int. 2009;29(9):1431–1438.
   PubMed Web of Science ®Google Scholar
  (b) Ren TY, Fan JG. What are the clinical settings and outcomes of lean NAFLD? Nat Rev Gastroenterol Hepatol. 2021;18(5):289–290.
   PubMed Web of Science ®Google Scholar
• Azzu V, Vacca M, Virtue S, et al. Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in nonalcoholic fatty liver disease. Gastroenterology. 2020;158(7):1899–1912.
   PubMed Web of Science ®Google Scholar
• Yang WS, Lee WJ, Funahashi T, et al. Plasma adiponectin levels in overweight and obese Asians. Obes Res. 2002;10(11):1104–1110.
   PubMedGoogle Scholar
• Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab. 2001;86(8):3815–3819.
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Toulis KA, Goulis DG, et al. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism Clin Exp. 2011;60(3):313–326.
   PubMed Web of Science ®Google Scholar
• Frithioff-Bøjsøe C, Lund MAV, Lausten-Thomsen U, et al. Leptin, adiponectin, and their ratio as markers of insulin resistance and cardiometabolic risk in childhood obesity. Pediatr Diabetes. 2020;21(2):194–202.
   PubMed Web of Science ®Google Scholar
• Norata GD, Raselli S, Grigore L, et al. Leptin:adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke. 2007;38(10):2844–2846.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Rinella ME, Sanyal AJ, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology. 2020;73(3):1194–1198. doi:10.1002/hep.31420.Epub 2021 Feb 6.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357.
   PubMed Web of Science ®Google Scholar
• Ballestri S, Lonardo A, Loria P. Nonalcoholic fatty liver disease activity score and Brunt’s pathologic criteria for the diagnosis of nonalcoholic steatohepatitis: what do they mean and do they agree? Hepatology. 2011;53(6):2142–2143; author reply 2143; author reply 3.
   PubMed Web of Science ®Google Scholar
• Das K, Das K, Mukherjee PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology. 2010;51(5):1593–1602.
   PubMed Web of Science ®Google Scholar
• Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389–398.
   PubMed Web of Science ®Google Scholar
• Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739–752.
   PubMed Web of Science ®Google Scholar